Zoekresultaten - Cui, Chengxu

Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐cente... door Jiang, Zhichao, Sun, Yongkun, Zhang, Wen, Cui, Chengxu, Yang, Lin, Zhou, Aiping

Volledige tekst Volledige tekst Volledige tekst

XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer door CUI, CHENGXU, SHU, CHANG, YANG, YI, LIU, JUNBAO, SHI, SHUPING, SHAO, ZHUJUN, WANG, NAN, YANG, TING, HU, SONGNIAN

Volledige tekst Volledige tekst Volledige tekst

Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial door Zhang, Wen, Du, Chunxia, Sun, Yongkun, Yang, Lin, Cui, Chengxu, Jiang, Zhichao, Wang, Chengfeng, Wang, Jinwang, Zhou, Aiping

Volledige tekst Volledige tekst Volledige tekst

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer door Song, Yan, Qu, Tao, Zhang, Honggang, Sun, Yongkun, Cui, Chengxu, Chi, Yihebali, Zhang, Wen, Wang, Xingyuan, Yang, Lin

Volledige tekst Volledige tekst Volledige tekst

UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens door Cui, Chengxu, Shu, Chang, Cao, Dandan, Yang, Yi, Liu, Junbao, Shi, Shuping, Shao, Zhujun, Wang, Nan, Yang, Ting, Liang, Hao, Zou, Shanshan, Hu, Songnian

Volledige tekst Volledige tekst Volledige tekst

Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy door Shang, Bingqing, Cao, Chuanzhen, Jiang, Weixing, Shi, Hongzhe, Bi, Xingang, Cui, Chengxu, Shou, Jianzhong, Zheng, Shan, Zhang, Jin, Zhou, Aiping, Li, Changling, Ma, Jianhui

Volledige tekst Volledige tekst Volledige tekst

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial door Qin, Shukui, Bi, Feng, Gu, Shanzhi, Bai, Yuxian, Chen, Zhendong, Wang, Zishu, Ying, Jieer, Lu, Yinying, Meng, Zhiqiang, Pan, Hongming, Yang, Ping, Zhang, Helong, Chen, Xi, Xu, Aibing, Cui, Chengxu, Zhu, Bo, Wu, Jian, Xin, Xiaoli, Wang, Jufeng, Shan, Jinlu, Chen, Junhui, Zheng, Zhendong, Xu, Li, Wen, Xiaoyu, You, Zhenyu, Ren, Zhenggang, Liu, Xiufeng, Qiu, Meng, Wu, Liqing, Chen, Feng

Volledige tekst Volledige tekst Volledige tekst

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label pha... door Xu, Jianming, Li, Yi, Fan, Qingxia, Shu, Yongqian, Yang, Lei, Cui, Tongjian, Gu, Kangsheng, Tao, Min, Wang, Xiuwen, Cui, Chengxu, Xu, Nong, Xiao, Juxiang, Gao, Quanli, Liu, Yunpeng, Zhang, Tao, Bai, Yuxian, Li, Wei, Zhang, Yiping, Dai, Guanghai, Ma, Dong, Zhang, Jingdong, Bai, Chunmei, Huang, Yunchao, Liao, Wangjun, Wu, Lin, Chen, Xi, Yang, Yan, Wang, Junye, Ji, Shoujian, Zhou, Hui, Wang, Yan, Ma, Zhuo, Wang, Yanqi, Peng, Bo, Sun, Jiya, Mancao, Christoph

Volledige tekst Volledige tekst Volledige tekst